AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$CGEM

Michaelson Jennifer sold $173K of CGEM

Michaelson Jennifer (Chief Scientific Officer) sold 8,000 shares of Cullinan Therapeutics, Inc. (CGEM) at $21.57 ($0.17M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Michaelson Jennifer
Published Sep 10, 2026, 1:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CGEM
Neutral
high confidence
Mentioned
$CGEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGEMNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting limited market impact.

02

Market read

Small insider sale with minimal price effect; primarily of interest to existing shareholders.

03

What to watch

Potential upcoming clinical data could make the sale more significant if timing aligns with trial milestones.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$CGEMNeutralHigh confidence
Context

Chief Scientific Officer Michaelson Jennifer sold 8,000 shares for $172,560 via a 10b5-1 plan on 2026-09-08.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale represents ~0.5% of insider holdings and is pre‑arranged, so market reaction is expected to be negligible.

Market effects

Sector

None; the transaction does not affect the biotech sector broadly.

Regional

No regional impact expected.

Global

Limited to CGEM shareholders.

Counterpoint

What could challenge this read

Some investors may view any insider selling as a negative signal despite the small size.

Key entities

  • Company
    Cullinan Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Insider
    Michaelson Jennifer

    Chief Scientific Officer of Cullinan Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CGEM insider trading history →

Related articles

OCT 2
MedAI 8/10

Cullinan Therapeutics starts zipalertinib NDA submission

Cullinan Therapeutics (CGEM) began submitting an NDA for zipalertinib in combination with chemotherapy for first-line lung cancer under FDA's real-time review program. The Phase 3 trial showed median progression-free survival of 14.5 months for the combination vs. 8.5 months for chemotherapy alone. Cullinan expects to complete the submission by year-end 2026. Shares closed at $14.53, down 5.34%.

mugglehead.com2 min
OCT 2
$CGEMMedAI 8/10

H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing

H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.

investing.com3 min